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Seroprevalence of Mycobacterium paratuberculosis in Patients with
Crohn’s Disease
Although the etiology of Crohn’s disease remains unclear, in
addition to genetic and other environmental factors, microor-
ganisms have been discussed as possibly playing an important
role. With increasing concern about the transmission of infec-
tious diseases from animals to humans, attention has refocused
on Mycobacterium paratuberculosis as a candidate organism in
the etiology of Crohn’s disease.
In a recent population-based case control study of sero-
prevalence of M. paratuberculosis in patients with Crohn’s dis-
ease and ulcerative colitis, the authors could not prove the
difference between inflammatory bowel disease patients and
healthy volunteers (1). The rate of positive enzyme-linked im-
munosorbent assay results was significantly higher for all study
groups. In conclusion, in this study, the M. paratuberculosis
seropositivity rate was approximately 35% for all groups, and
there was no difference in rates among Crohn’s disease pa-
tients, ulcerative colitis patients, healthy controls, and unaf-
fected siblings (1).
We also examined the seroprevalence of M. paratubercu-
losis in 42 Crohn’s disease patients and 34 healthy, randomly
selected volunteers in Debrecen, Hungary. The relatively
small number of cases limited our consideration of the pos-
sibilities. Adult patients of both sexes were included. All
patients had previously received routine Mycobacterium bo-
vis bacillus Calmette-Gue´rin vaccinations in childhood but
had no evidence of tuberculosis in their case histories. The
diagnosis of Crohn’s disease was made using the formally
accepted criteria. We used the same adapted enzyme-linked
immunosorbent assay (IDEXX Laboratories) as Dr. Bern-
stein did for serum antibodies to M. paratuberculosis, as Dr.
Collins advised (he suggested that we test human sera from
healthy blood donors to establish, by analysis of frequency
distributions, what a reasonable approximate cutoff level
might be for Hungarian patients). We used sera from the
healthy controls to set the upper limit of normal with 95%
confidence. A positive test for a human serum sample was
defined, based on the results with these sera, by a test result
equivalent to the mean S/P ratio (0.079) plus 2 standard
deviations (2  0.123), i.e., 0.325. We proved that only
approximately 9% of the controls were seropositive for M.
paratuberculosis, in contrast to 33.3% of Crohn’s disease
patients.
Even given the small number of subjects in our study,
these observations invite further surveys to elucidate the
results, as we think they are definitely more than accidental.
Our findings may enrich other findings and suggest that M.
paratuberculosis has certain importance in Crohn’s disease
after all, but further multicenter research is required for a
comparison of results.
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Authors’ Reply
We appreciate Dr. Barta’s interest in our paper. The Hun-
garian seroprevalence of Mycobacterium paratuberculosis raises
some important issues. First, Dr. Barta is reporting a preva-
lence in controls comparable to that which has been reported
previously in Denmark and Wisconsin (less than 10%) (1) but
much lower than that of a control population in Manitoba (2).
This may suggest that the population of Manitoba is truly more
exposed to M. paratuberculosis in general than three other
populations from disparate areas of the world. Second, the
prevalence of 33% among Crohn’s disease patients was com-
parable to the seroprevalence in Manitoba but much higher
than that reported in Denmark and Wisconsin (1). Two
strengths of our study in Manitoba are that we studied a rea-
sonably large sample (nearly 1,000 subjects) and that both
cases and controls were population based. The interesting find-
ings from Hungary underscore the need for larger studies with
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well-matched cases and controls to determine if seropositivity
to M. paratuberculosis varies by region, is associated with
Crohn’s disease, or is different in population-based versus se-
lected populations. While our results are different than those
from Hungary, our findings are mutually provocative, and we
agree with Dr. Barta’s plea for further data to help clarify the
issues.
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